Research output: Contribution to journal › Article › peer-review
Dose-dependent suppression of human glioblastoma xenograft growth by accelerator-based boron neutron capture therapy with simultaneous use of two boron-containing compounds. / Kanygin, Vladimir; Razumov, Ivan; Zaboronok, Alexander et al.
In: Biology, Vol. 10, No. 11, 1124, 11.2021.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Dose-dependent suppression of human glioblastoma xenograft growth by accelerator-based boron neutron capture therapy with simultaneous use of two boron-containing compounds
AU - Kanygin, Vladimir
AU - Razumov, Ivan
AU - Zaboronok, Alexander
AU - Zavjalov, Evgenii
AU - Kichigin, Aleksandr
AU - Solovieva, Olga
AU - Tsygankova, Alphiya
AU - Guselnikova, Tatiana
AU - Kasatov, Dmitrii
AU - Sycheva, Tatiana
AU - Mathis, Bryan J.
AU - Taskaev, Sergey
N1 - Funding Information: Funding: The research was supported by the RUSSIAN FOUNDATION FOR BASIC RESEARCH, scientific project No. 18-29-01007. The research related to quantitative chemical analysis of organs and tissues was supported by the MINISTRY OF SCIENCE AND HIGHER EDUCATION OF THE RUSSIAN FEDERATION, project No. 121031700315-2. The neutron generation study was supported by the RUSSIAN SCIENCE FOUNDATION, project No. 19-72-30005. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11
Y1 - 2021/11
N2 - (1) Background: Developments in accelerator-based neutron sources moved boron neutron capture therapy (BNCT) to the next phase, where new neutron radiation parameters had to be studied for the treatment of cancers, including brain tumors. We aimed to further improve accelerator-BNCT efficacy by optimizing dosimetry control, beam parameters, and combinations of boronophenylalanine (BPA) and sodium borocaptate (BSH) administration in U87MG xenograftbearing immunodeficient mice with two different tumor locations. (2) Methods: The study included two sets of experiments. In Experiment #1, BPA only and single or double irradiation in higher doses were used, while, in Experiment #2, BPA and BSH combinations and single or double irradiation with dosage adjustment were analyzed. Mice without treatment or irradiation after BPA or BPA+BSH injection were used as controls. (3) Results: Irradiation parameter adjustment and BPA and BSH combination led to 80–83% tumor-growth inhibition index scores, irradiation:BNCT ratios of 1:2, and increases in animal life expectancy from 9 to 107 days. (4) Conclusions: Adjustments in dosimetry control, calculation of irradiation doses, and combined use of two10B compounds allowed for BNCT optimization that will be useful in the development of clinical-trial protocols for accelerator-based BNCT.
AB - (1) Background: Developments in accelerator-based neutron sources moved boron neutron capture therapy (BNCT) to the next phase, where new neutron radiation parameters had to be studied for the treatment of cancers, including brain tumors. We aimed to further improve accelerator-BNCT efficacy by optimizing dosimetry control, beam parameters, and combinations of boronophenylalanine (BPA) and sodium borocaptate (BSH) administration in U87MG xenograftbearing immunodeficient mice with two different tumor locations. (2) Methods: The study included two sets of experiments. In Experiment #1, BPA only and single or double irradiation in higher doses were used, while, in Experiment #2, BPA and BSH combinations and single or double irradiation with dosage adjustment were analyzed. Mice without treatment or irradiation after BPA or BPA+BSH injection were used as controls. (3) Results: Irradiation parameter adjustment and BPA and BSH combination led to 80–83% tumor-growth inhibition index scores, irradiation:BNCT ratios of 1:2, and increases in animal life expectancy from 9 to 107 days. (4) Conclusions: Adjustments in dosimetry control, calculation of irradiation doses, and combined use of two10B compounds allowed for BNCT optimization that will be useful in the development of clinical-trial protocols for accelerator-based BNCT.
KW - Accelerator-based neutron source
KW - Animal tumor model
KW - Boron compounds
KW - Boron neutron capture therapy
KW - Boronophenylalanine
KW - Glioblastoma
KW - Sodium borocaptate
UR - http://www.scopus.com/inward/record.url?scp=85119015733&partnerID=8YFLogxK
U2 - 10.3390/biology10111124
DO - 10.3390/biology10111124
M3 - Article
C2 - 34827117
AN - SCOPUS:85119015733
VL - 10
JO - Biology
JF - Biology
SN - 2079-7737
IS - 11
M1 - 1124
ER -
ID: 34642422